Evidence map›Paper›PMID 33226493›Full record

ArticleBreast cancer research and treatment2021

Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.

C Louwrens Braal, Koen G A M Hussaarts, Lieke Seuren, Esther Oomen-deHoop, Peter de Bruijn, Stefan A J Buck, Monique E M M Bos, Martine F Thijs-Visser, Hanneke J M Zuetenhorst, Daniëlle Mathijssen-van Stein and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

C Louwrens BraalDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands. c.braal@erasmusmc.nl.ORCID http://orcid.org/0000-0003-3600-9851
Koen G A M HussaartsDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.
Lieke SeurenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.
Esther Oomen-deHoopDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.
Peter de BruijnDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.
Stefan A J BuckDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.
Monique E M M BosDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.
Martine F Thijs-VisserDepartment of Medical Oncology, Ikazia Hospital, Rotterdam, The Netherlands.
Hanneke J M ZuetenhorstDepartment of Internal Medicine, Franciscus Gasthuis & Vlietland, Schiedam, The Netherlands.
Daniëlle Mathijssen-van SteinDepartment of Internal Medicine, Franciscus Gasthuis & Vlietland, Schiedam, The Netherlands.
Mijntje B VastbinderDepartment of Internal Medicine, IJsselland Hospital, Capelle Aan Den IJssel, The Netherlands.
Roelof W F van LeeuwenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.
Teun van GelderDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Stijn L W KoolenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.
Agnes JagerDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.
Ron H J MathijssenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, CN, PO Box 2040, 3015, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33226493
PMCPMC8025281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.